Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

Abstract Background The hypomethylating agent decitabine is the standard therapy for intermediate or high risk myelodysplastic syndrome (MDS). Methods In this trial, 191 adult patients with intermediate/high risk MDS (IPSS score ≥ 0.5) randomly received decitabine using a standard regimen (20 mg/m2/...

Full description

Bibliographic Details
Main Authors: Hui Liu, Hao Jiang, Hongyan Tong, Ruixiang Xia, Linhua Yang, Hongguo Zhao, Jian Ouyang, Hai Bai, Hui Sun, Li Hou, Ming Jiang, Yun Zeng, Zhuogang Liu, Aibin Liang, Yinghua Xie, Kang Yu, Zhimin Zhai, Li Liu, Jinsong Jia, Rong Fu, Zonghong Shao
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Cancer Medicine
Subjects:
complete remission
decitabine
hypomethylating agent
myelodysplastic syndromes
overall survival
Online Access:https://doi.org/10.1002/cam4.5922

Internet

https://doi.org/10.1002/cam4.5922

Similar Items